These rodent model behavioral responses to partial knockdown of the NET gene are consistent with clinical MDD treatments using high-affinity blockers of NET, such as SNRIs, which enhance the synaptic activity of NE22. This evidence concerns the gene SLC6A2 and major depressive disorder.